Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | FABP4 | P15090 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | STAT3 | P40763 | 13/20 | 0.72 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Andrographolide SCHEMBL12777642 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL12206780 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL16204143 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL15263160 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL14029461 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL19704806 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL24806666 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL62263 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL20828610 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 | |
| Andrographolide SCHEMBL3668454 | 1.00 | NR1H4 (1.00) | NR1H4TP53CYP3A4FABP4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632909-B1 | SALT AND CRYSTAL FORM OF MODIFIED ANDROGRAPHOLIDE COMPOUND AND PREPARATION METHOD THEREOF | Heilongjiang zhenbaodao pharmaceutical co ltd (CN) | 2023-07-12 | — | — | EP | disclosed |
| US-20210284630-A1 | SALT AND CRYSTAL FORM OF MODIFIED ANDROGRAPHOLIDE COMPOUND AND PREPARATION METHOD THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-09-16 | — | — | US | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| US-10717720-B2 | Modified compound of andrographolide | HEILONGJIANG ZHENBAODAO PHARMACEUTICAL CO., LTD. (CN) | 2020-07-21 | — | — | US | disclosed |
| EP-3632909-A1 | SALT AND CRYSTAL FORM OF MODIFIED ANDROGRAPHOLIDE COMPOUND AND PREPARATION METHOD THEREOF | Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | MEDSHINE DISCOVERY INC. (CN) | 2018-12-06 | — | — | US | disclosed |
| EP-3381912-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. (CN) | 2018-10-03 | — | — | EP | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| US-8367720-B2 | Andrographolide derivatives and use thereof in manufacture of medicaments | PANORAMA RESEARCH INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110077295-A1 | ANDROGRAPHOLIDE DERIVATIVES AND USE THEREOF IN MANUFACTURE OF MEDICAMENTS | PANORAMA RESEARCH INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-7625945-B2 | Andrographolide and analogues as inhibitors of TNFα and IL-1β expression | Hutchison MediPharma Enterprises Ltd. (BS) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077295-A1 | ANDROGRAPHOLIDE DERIVATIVES AND USE THEREOF IN MANUFACTURE OF MEDICAMENTS | ALOX15B, MRPS18A, ALOX15 | NR1H4 2936/4885TP53 104/4885CYP3A4 1356/4885 |
| US-20210284630-A1 | SALT AND CRYSTAL FORM OF MODIFIED ANDROGRAPHOLIDE COMPOUND AND PREPARATION METHOD THEREOF | CYP21A2, CYP4A11, CYP11B1 | NR1H4 1343/4885TP53 2840/4885CYP3A4 331/4885 |
| US-10717720-B2 | Modified compound of andrographolide | CYP11B2, CYP11B1, DUSP23 | NR1H4 1164/4885TP53 1477/4885CYP3A4 668/4885 |
| US-20180346438-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | CYP11B2, CYP11B1, DUSP23 | NR1H4 1164/4885TP53 1477/4885CYP3A4 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.